Similar articles

• A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.

  Perreault S, Hamilton VH, Lavoie F, Grover S. Perreault S, et al. Cardiovasc Drugs Ther. 1997 Jan;10(6):787-94. doi: 10.1007/BF00053037. Cardiovasc Drugs Ther. 1997. PMID: 9110123 Clinical Trial.
• Economics of lipid lowering with HMG CoA reductase inhibitors.

  Illingworth DR. Illingworth DR. Clin Cardiol. 1995 Jun;18(6):295, 363. doi: 10.1002/clc.4960180616. Clin Cardiol. 1995. PMID: 7664501 No abstract available.
• Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.

  Martens LL, Guibert R. Martens LL, et al. Clin Ther. 1994 Nov-Dec;16(6):1052-62; discussion 1036. Clin Ther. 1994. PMID: 7697684 Review.
• Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.

  Jacobson TA. Jacobson TA. Curr Opin Lipidol. 1997 Dec;8(6):369-74. doi: 10.1097/00041433-199712000-00008. Curr Opin Lipidol. 1997. PMID: 9412778 Review.
• Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.

  Ginsberg HN. Ginsberg HN. Clin Cardiol. 1995 Jun;18(6):307-15. doi: 10.1002/clc.4960180605. Clin Cardiol. 1995. PMID: 7664504 Review.